AGC Biologics Completes pDNA and mRNA Line Expansion in Heidelberg

Contributed by: Business Wire

Logo

Tags

Stem Cells

Biotechnology

Manufacturing

Health

Pharmaceutical

Health Technology

Research

Genetics

Engineering

Science

Chemicals/Plastics

AGC Biologics

More Like This

GlobeNewswire associated0

Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma

PR Newswire associated0

BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx

(Graphic: Business Wire)

PHC Unveils Prototype of LiCellGrow, New Cell Expansion System to Support Development of Cell and Gene Therapy Products Manufacturing Process

PR Newswire associated0

EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment

TriLink BioTechnologies® Cuts Ribbon on New San Diego Facility for Late Phase mRNA Drug Substance Production (Photo: TriLink BioTechnologies®)

TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production

Merck invests €70 million to triple its antibody-drug conjugate (ADC) manufacturing capacity and upgrade 3200 m2 at its BioConjugation Center of Excellence in St. Louis, Missouri, USA. (Photo: Business Wire)

Merck Invests €70 Million to Expand ADC Manufacturing for Novel Cancer Therapies

ViroCell Biologics Completes Oversubscribed Financing

ViroCell Biologics Signs Master Services Agreement With Prominent NCI-Designated Cancer Center